跳至主要内容
临床试验/NCT04670393
NCT04670393已完成不适用

Impact of the Administration of an Antioxidant Food Supplement Associated With Oral Probiotics on the Ovarian Oxidative Stress Profile and the Intestinal Microbiota Function in the in Vitro Fertilization Cycle of Patients With Polycystic Ovarian Syndrome

Fertypharm2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2020年12月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
20
试验地点
2
主要终点
Number of MII oocytes

研究概览

简要总结

The aim of the study is to study the effect of an antioxidant food supplement associated with probiotics on the oocyte quality response, oxidative stress and microbiota function in an in vitro fertilization cycle in patients with polycystic ovarian syndrome

详细描述

After being informed about the study, all patients meeting the inclusion/exclusion criteria and giving written informed consent will be randomized in a double-blind manner in a ratio 1:1 to receive the antioxidant supplementation associated with probiotics (Myo-Inositol, D-Chiro-Inositol, folic acid, selenium, vitamin D, Melatonin, Lactobacillus rhamnosus, Lactobacillus cripatus and Lactobacillus plantarum) or placebo (folic acid) once daily.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 38 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Age:18-38 years old
  • Diagnosis of PCOS according to compliance with the Rotterdam criteria
  • BMI >= 25

排除标准

  • Hormonal contraceptive, insulin sensitizers such as metformin, inositols, antioxidants, vitamin supplements except folic acid, GnRH analogs, steroidal drugs or others with anti-inflammatory properties, antibiotics, probiotics, laxatives use in the 3 months prior to recruitment
  • Tobacco consumption in last 12 months
  • Endometriosis, hydrosalpinx not surgically treated, acute or chronic inflammatory diseases, systemic immune diseases, other endocrine diseases or dysfunctions except for PCOS and subclinical hypothyroidism treated with low doses of levothyroxine (eg congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumors, Diabetes Millitus, hyperprolactinemia, hyperglycemia), active neoplastic disease or without evidence of complete remission for at least 5 years,
  • Active participation in an active weight reduction program or hypocaloric diet during the study period. No change in habits will be taught during the study period
  • Hypersensitivity to any of the components in the Fertybiotic Mujer Plus® formulation

结局指标

主要结局

Number of MII oocytes

时间窗: 3 months in follicular puncture visit

次要结局

  • LH(Baseline and about 2,5 months when the cycle treatment starts)
  • Insulin(Baseline and about 2,5 months when the cycle treatment starts)
  • SCFA(Baseline and about 2,5 months when the cycle treatment starts)
  • Oocytes(3 months in follicular puncture visit)
  • FSH(Baseline and about 2,5 months when the cycle treatment starts)
  • Sirtuin(3 months in follicular puncture visit)
  • Pregnancy rate(Through study completion, an average of 1 year)
  • Glucose(Baseline and about 2,5 months when the cycle treatment starts)
  • Androstendione(Baseline and about 2,5 months when the cycle treatment starts)
  • Testosterone(Baseline and about 2,5 months when the cycle treatment starts)
  • Glutation(3 months in follicular puncture visit)
  • Zonulin(Baseline and about 2,5 months when the cycle treatment starts)
  • Follicles(3 months in follicular puncture visit)
  • Stimulation days(3 months in follicular puncture visit)
  • MDA(Baseline (plasma) and 3 months in follicular puncture visit (plasma and follicular puncture))
  • TAC(Baseline (plasma) and 3 months in follicular puncture visit (plasma and follicular puncture))
  • 8-OH-desoxiguanosin(3 months in follicular puncture visit)
  • Gonadotropin UI(3 months in follicular puncture visit)
  • Live birth rate(Through study completion, an average of 1 year)

研究者

发起方
Fertypharm
申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验